Rheumatoid Arthritis: A Comprehensive Review of Etiology, Pathophysiology, and Innovative Therapeutic Advancements

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, cartilage degradation, and bone erosion, ultimately leading to joint deformities and functional impairment. Affecting approximately 1% of the global population, RA imposes a significant burden on healthcare systems and patient quality of life. The disease pathogenesis involves a complex interplay between genetic predisposition, environmental triggers, and dysregulated immune responses. While genome-wide association studies (GWAS) have identified multiple susceptibility loci, genetic factors alone do not fully account for disease onset. Environmental influences, such as smoking, obesity, and microbial dysbiosis, contribute to immune tolerance breakdown, leading to aberrant activation of T cells, B cells, and proinflammatory cytokines, including TNF-α and IL-6. Conventional therapies, including disease-modifying antirheumatic drugs (DMARDs) and biologics, have significantly improved disease outcomes but remain limited by non-responsiveness in a subset of patients and long-term safety concerns. Recent advances in nanotechnology, biomimetic drug carriers, and precision medicine offer promising avenues for overcoming these challenges. Innovative therapeutic approaches, such as in situ hydrogels targeting neutrophil extracellular traps (NETs), liposomal drug delivery systems enhancing bioavailability, and nanoparticle-based immune modulation, provide new hope for improving treatment efficacy and reducing systemic side effects. This review comprehensively explores RA's multifactorial etiology, immunopathogenesis, and emerging therapeutic strategies, highlighting novel drug delivery systems and personalized treatment approaches that may revolutionize RA management.